comparemela.com
Home
Live Updates
Philipm Fortier - Breaking News
Pages:
Latest Breaking News On - Philipm fortier - Page 1 : comparemela.com
AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels in the brain for the treatment .
United states
City of
United kingdom
Olmsted county
Research triangle park
North carolina
Philipm fortier
Nicolasm phielipp
Krystof bankiewicz
Brain neurotherapy bio inc
European study group on atypical parkinsonisms
University of california irvine
Quest research institute
Bayer ag
Asklepios biopharmaceutical inc
Drug administration
Bayer: first patient recruited for MSA -November 17, 2023 at 11:36 am EST
Asklepios BioPharmaceutical , a 100%-owned and independently-operated gene therapy company as a subsidiary of Bayer, announces the first randomized patient in the AB-1005 Phase 1 gene therapy trial.
Philipm fortier
Asklepios biopharmaceutical
vimarsana © 2020. All Rights Reserved.